Boniatti, J;
Januskaite, P;
da Fonseca, LB;
Viçosa, AL;
Amendoeira, FC;
Tuleu, C;
Basit, AW;
... Ré, MI; + view all
(2021)
Direct powder extrusion 3d printing of praziquantel to overcome neglected disease formulation challenges in paediatric populations.
Pharmaceutics
, 13
(8)
, Article 1114. 10.3390/pharmaceutics13081114.
Preview |
Text
pharmaceutics-13-01114-v2.pdf - Published Version Download (6MB) | Preview |
Abstract
For the last 40 years, praziquantel has been the standard treatment for schistosomiasis, a neglected parasitic disease affecting more than 250 million people worldwide. However, there is no suitable paediatric formulation on the market, leading to off-label use and the splitting of commercial tablets for adults. In this study, we use a recently available technology, direct powder extrusion (DPE) three-dimensional printing (3DP), to prepare paediatric Printlets™ (3D printed tablets) of amorphous solid dispersions of praziquantel with Kollidon® VA 64 and surfactants (Span™ 20 or Kolliphor® SLS). Printlets were successfully printed from both pellets and powders obtained from extrudates by hot melt extrusion (HME). In vitro dissolution studies showed a greater than four-fold increase in praziquantel release, due to the formation of amorphous solid dispersions. In vitro palatability data indicated that the printlets were in the range of praziquantel tolerability, highlighting the taste masking capabilities of this technology without the need for additional taste masking excipients. This work has demonstrated the possibility of 3D printing tablets using pellets or powder forms obtained by HME, avoiding the use of filaments in fused deposition modelling 3DP. Moreover, the main formulation hurdles of praziquantel, such as low drug solubility, inadequate taste, and high and variable dose requirements, can be overcome using this technology.
| Type: | Article |
|---|---|
| Title: | Direct powder extrusion 3d printing of praziquantel to overcome neglected disease formulation challenges in paediatric populations |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/pharmaceutics13081114 |
| Publisher version: | https://doi.org/10.3390/pharmaceutics13081114 |
| Language: | English |
| Additional information: | © 2021 by the Authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | 3D printing; 3D printed drug products; printing pharmaceuticals and medicines; personalized therapeutics; oral drug delivery systems and technologies; taste masking; translational pharmaceutics; material extrusion additive manufacturing; M3DIMAKER printer; pediatric treatments |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10132356 |
Archive Staff Only
 |
View Item |
